Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the dosage ladder works in practice, and what sits behind each step
You've found the dosage chart, here's how to read it without overcomplicating things
Most people searching for an oral semaglutide weight loss dosage chart want the same thing: a clear table they can look at and understand. So here it is.
| Step | Daily dose | Minimum duration |
|---|---|---|
| 1 | 1.5 mg | 4 weeks |
| 2 | 4 mg | 4 weeks |
| 3 | 9 mg | 4 weeks |
| 4 (maintenance) | 25 mg | Ongoing |
The reason the schedule is graduated is biology, not bureaucracy. Oral semaglutide is absorbed through the gut wall alongside an absorption enhancer called SNAC. At higher doses, the GI system can push back, nausea, loose stools, that queasy first-two-weeks feeling that tends to pass. The slow ramp gives your body time to settle at each level before the dose climbs again. A fuller breakdown of the dosage framework goes into the pharmacology behind the stepped approach.
One thing the chart cannot tell you: how quickly you personally will move through it. A prescriber may hold you at 9 mg longer if tolerability is a challenge, or confirm you're ready for 25 mg once you've had a month with good adherence. If you want to understand how semaglutide pill dosage works for weight loss, including what influences each step, that page covers the detail behind the numbers. The chart is the scaffold; your clinical review fills in the detail.
It's worth knowing that the 3 mg, 7 mg and 14 mg tablet strengths you might see mentioned online belong to Rybelsus, the oral semaglutide product licensed for type 2 diabetes, not for weight management. Those strengths are not part of the Wegovy tablet schedule and should not be confused with it.
Where the 25 mg target dose sits in the evidence base
If you've spent any time looking at the semaglutide tablets weight loss dosage chart alongside trial data, you may have wondered how the oral route compares to the weekly injection. The honest answer is: it's close, but not identical.
In the OASIS 4 phase-3 trial (307 adults with obesity or overweight plus at least one weight-related condition, over 64 weeks) average weight loss was around 13.6% compared with about 2.4% in the placebo group. Among participants who stayed fully adherent to the treatment throughout, that figure rose to approximately 16.6%. The MHRA cited this evidence when it approved the Wegovy tablet on 11 June 2026, as detailed in the GOV.UK announcement.
For context, the injectable Wegovy at 2.4 mg produced around 15% average weight loss over 68 weeks in the STEP 1 trial, and the newer 7.2 mg injectable dose narrows the gap with tirzepatide further. The oral route's ~13–17% range reflects the absorption variability that comes with any tablet taken through the gut.
Adherence to the morning ritual matters more here than with an injection. Missing the 30-minute fast, taking the tablet with coffee, or swallowing it with a large glass of water all reduce the amount of semaglutide actually reaching your bloodstream. The practical guide to oral dosing covers the exact routine and common mistakes.
For people with obesity but without diabetes (the group most of these searches come from) the licensed indication covers BMI 30 or above, or 27 to 29.9 with at least one weight-related condition. There's dedicated reading on dosage for non-diabetic adults if that's your situation.
What the chart doesn't cover, and why that matters before you start
A dosage chart is a snapshot. It tells you the numbers and the sequence. It doesn't tell you what to do if nausea at 4 mg is making it hard to eat, whether you should push through or pause, or whether your other medications or health history make the Wegovy tablet the right choice for you in the first place.
Understandably, a lot of people feel a mix of optimism and slight wariness at this stage. The tablet is genuinely new (the MHRA only approved it in summer 2026) and the questions stack up fast. That's fair. Prescription-only medicines carry that weight precisely because the decisions around them aren't one-size-fits-all.
As a Prescription-Only Medicine, Wegovy tablets require a clinical assessment before any prescription can be written. At nume, sorry, at our pharmacy, that assessment is carried out personally by a GPhC-registered Independent Prescriber on the same day you submit your consultation. A real clinician, not a routing algorithm, reads your health history, checks for contraindications, and confirms the dosage schedule that's right for your situation. Details on our clinical team are on the clinical team profile page.
A note on cost while you're here: the Wegovy tablet is available as a private prescription only, NICE has not yet appraised it for NHS use. An overview of what private treatment involves financially is on the Wegovy pill price page, which also explains what's included in a single transparent price. Answers to common questions about getting started are covered in our FAQs.
If you'd like to explore whether the tablet fits your circumstances, the first step is a free consultation with our prescribers, no commitment, no obligation, just a proper clinical conversation. Check your eligibility and start that conversation here.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.